Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18345387 | 0.85 | DGAT1 (0.39) | DGAT1ELANEGAAHDAC6HDAC1 | |
| SCHEMBL1609396 | 0.83 | CA12 (0.41) | DGAT1ELANEMEN1GAAKMT2A | |
| SCHEMBL16653875 | 0.83 | DGAT1 (0.38) | DGAT1ELANEHDAC6HDAC1HDAC2 | |
| SCHEMBL28763660 | 0.81 | DGAT1 (0.41) | DGAT1ELANEMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL9176523 | 0.81 | CA1 (0.40) | DGAT1ELANEMEN1GAAKMT2A | |
| SCHEMBL8588817 | 0.80 | ELANE (0.39) | DGAT1ELANEGAAHDAC6HDAC1 | |
| SCHEMBL9410014 | 0.79 | DGAT1 (0.42) | DGAT1ELANEMEN1GAAKMT2A | |
| Hydrogen Peroxide SCHEMBL28079587 | 0.78 | DGAT1 (0.43) | DGAT1ELANEMEN1GAAKMT2A | |
| SCHEMBL18345454 | 0.78 | DGAT1 (0.34) | DGAT1ELANEHDAC6HDAC1HDAC2 | |
| SCHEMBL14212529 | 0.77 | DGAT1 (0.41) | DGAT1ELANEMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| CN-115197098-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2023-08-08 | — | — | CN | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-113272272-B | RIP1 inhibitors | 圣瑞诺有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115197098-A | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108467-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-08-19 | — | — | CN | disclosed |
| CN-108368101-B | Selective NR2B antagonists | 百时美施贵宝公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3883918-A1 | RIP1 INHIBITORS | Sironax Ltd (KY) | 2021-09-29 | — | — | EP | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
| CN-113272272-A | RIP1 inhibitors | 圣瑞诺有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-10-17 | — | — | US | disclosed |
| WO-2011159177-A1 | IMPROVED AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2011-12-22 | — | — | WO | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615699-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004092124-A2 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-0759919-A1 | NEW AZOLIDINEDIONES AS ANTIHYPERGLYCEMIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | ALKBH3, ALKBH1, ALKBH2 | DGAT1 1122/4885ELANE 2478/4885MEN1 3894/4885 |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | DGAT1 3833/4885ELANE 425/4885MEN1 3991/4885 |
| US-20210284598-A1 | RIP1 Inhibitors | RIPK1, RIPK3, RIPK4 | DGAT1 1255/4885ELANE 2250/4885MEN1 1669/4885 |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK4 | DGAT1 2350/4885ELANE 3355/4885MEN1 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.